Stephen S. Yoder
Net Worth

Last updated: 13 Jun 2016

What is Stephen S. Yoder net worth?

The estimated net worth of Mr. Stephen S. Yoder is at least $6,650,730 as of 13 Jun 2016. He owns shares worth $79,560 as insider and has received compensation worth at least $6,571,170 in Pieris Pharmaceuticals, Inc..

What is the salary of Stephen S. Yoder?

Mr. Stephen S. Yoder salary is $730,130 per year as Chief Executive Officer, Pres & Director in Pieris Pharmaceuticals, Inc..

How old is Stephen S. Yoder?

Mr. Stephen S. Yoder is 49 years old, born in 1976.

What stocks does Stephen S. Yoder currently own?

As insider, Mr. Stephen S. Yoder owns shares in one company:

Company	Title	Shares	Price per share	Total value
Pieris Pharmaceuticals, Inc. (PIRS)	Chief Executive Officer, Pres & Director	6,000	$13.26	$79,560

What does Pieris Pharmaceuticals, Inc. do?

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.